Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 7931158
• 负责人: ROBERT Alan FIGLIN
• 金额: $ 5万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7931158
• 关键词: Achievement; Adult; Animals; Antibodies; Appointment; Area; Award; Basic Science; Beds; Biological; Biology; Biomedical Engineering; Biopolymers; Bone Marrow Transplantation; Book Chapters; Brain; Breast; Budgets; California; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Control; Chemical Engineering; Chemistry; Cities; City of Hope Comprehensive Cancer Center; Clinical; Clinical Protocols; Clinical Research; Clinical Trials; Collaborations; Colorectal; Communities; Comprehensive Cancer Center; Correlative Study; Critiques; Development; Developmental Biology; Developmental Therapeutics Program; Disease; Doctor of Philosophy; Education; Evaluation; Evolution; Faculty; Follow-Up Studies; Foundations; Funding; Future; Goals; Grant Review; Growth; Hematologic Neoplasms; Hematopoietic stem cells; Hospitals; Human; Human Resources; Image; Immunobiology; Immunotherapeutic agent; Industry; Information Sciences; Institution; Investigational New Drug Application; Investments; Laboratories; Leadership; Link; Lymphoma; Malignant Neoplasms; Malignant neoplasm of lung; Medical Oncology; Minority Groups; Mission; Musculoskeletal; Operative Surgical Procedures; Outpatients; Patients; Peer Review Grants; Phase; Phase II Clinical Trials; Population Research; Population Sciences; Positioning Attribute; Prostate; Publications; Publishing; Recruitment Activity; Reproduction spores; Request for Applications; Research; Research Activity; Research Infrastructure; Research Personnel; Research Support; Resource Sharing; Role; Solid Neoplasm; Stem cells; Strategic Planning; Surveys; T-Lymphocyte; Therapeutic; Therapy Clinical Trials; Time; Translating; Translational Research; Vision; Visit; base; cost; high throughput screening; infrastructure development; innovation; leukemia/lymphoma; leukemic stem cell; malignant breast neoplasm; member; nanoparticle; professor; programs; sarcoma; small molecule; statistics; success; survivorship; symptom management; translational study

DESCRIPTION (provided by applicant): This renewal application requests funding for the 25th through 29th years of the NCI Cancer Center Support Grant of the City of Hope Comprehensive Cancer Center. The Center now has five research programs: one basic research Program (Cancer Biology, CB); three clinical/translational research Programs (Developmental Cancer Therapeutics, DCT; Cancer Immunotherapeutics, Cl; Hematologic Malignancies, HM); and one population research program (Cancer Control and Population Sciences, CCPS). Twelve shared resources support the scientific activities of the members, including two new cores (Small Animal Imaging; Clinical Immunobiology Correlative Studies Laboratory). Three developing cores are proposed (High Throughput Screening; Synthetic & Biopolymer Chemistry; Survey Research). Membership has grown by 45% in the preceding program period with the recruitment of 37 new Full Members, including several key senior leaders (Richard Jove, PhD, Deputy Director; R. Figlin, MD, Associate Director [AD] for Clinical Research). Other key leadership positions have also been filled through internal appointments (Smita Bhatia, MD, MPH, AD for Population Research; Joyce Niland, PhD, AD for Information Sciences; and Yun Yen, MD, PhD, AD for Translational Research). As a result of our program restructuring, recruitment and infrastructure development, we now believe we have a Center where our five Programs represent a continuum in which basic and translational studies in the basic science Program, CB, and one clinical Program, DCT, can be linked to Phase I and II clinical protocols in all three clinical programs (DCT, Cl, HM) and follow-up studies in survivorship and symptom management in the population sciences program (CCPS). All these activities are made possible by a Center and Institutional infrastructure that supports basic and translational research in biological and, now, small molecule approaches to cancer in an extraordinarily collaborative fashion. Such interaction has resulted in the Center's first SPORE, in lymphoma; a recent W.M. Keck Foundation award; and the renewal of eight large, multi-investigator awards. During the next funding period, we will build on these achievements so that the City of Hope Comprehensive Cancer Center takes the next step in its evolution: translating more laboratory discoveries into innovative clinical trials and developing disease-based research programs. The 82 Full Members and 90 Associate Members of the Center Programs have published 1001 articles, book chapters, etc., since the last competitive grant review. Of these, 28% are intraprogrammatic and 22% are interprogrammatic publications.

描述（由申请人提供）：本续签申请要求为希望之城综合癌症中心的 NCI 癌症中心支持补助金提供第 25 至 29 年的资金。中心现有五个研究项目：基础研究项目1个（Cancer Biology，CB）；三个临床/转化研究项目（发育性癌症治疗，DCT；癌症免疫治疗，Cl；血液恶性肿瘤，HM）；以及一项人口研究计划（癌症控制和人口科学，CCPS）。十二个共享资源支持成员的科学活动，其中包括两个新核心（小动物成像；临床免疫生物学相关研究实验室）。提出了三个开发核心（高通量筛选；合成和生物聚合物化学；调查研究）。在上一个计划期间，会员人数增长了 45%，招募了 37 名新的正式会员，其中包括几位重要的高级领导者（副主任 Richard Jove 博士；R. Figlin 医学博士，临床研究副主任 [AD]）。其他关键领导职位也通过内部任命填补（Smita Bhatia，医学博士、公共卫生硕士、人口研究副主任；Joyce Niland，博士、信息科学副主任；Yun Yen，医学博士、博士、转化研究副主任）。经过我们的项目重组、招聘和基础设施开发，我们现在相信我们拥有一个中心，我们的五个项目代表了一个连续体，其中基础科学项目 CB 和一个临床项目 DCT 的基础和转化研究可以在其中进行。与所有三个临床项目（DCT、Cl、HM）中的 I 期和 II 期临床方案以及人口科学项目 (CCPS) 中生存和症状管理的后续研究相关联。所有这些活动都是通过一个中心和机构基础设施实现的，该中心和机构基础设施以非常协作的方式支持生物学和现在的小分子癌症方法的基础和转化研究。这种相互作用导致了该中心在淋巴瘤中的第一个 SPORE；最近的 W.M.凯克基金会奖；并更新了八个大型、多研究者奖项。 在下一个资助期内，我们将在这些成就的基础上再接再厉，使希望之城综合癌症中心的发展迈出下一步：将更多的实验室发现转化为创新的临床试验，并开发基于疾病的研究项目。自上次竞争性拨款审查以来，该中心计划的 82 名正式会员和 90 名准会员已发表了 1001 篇文章、书籍章节等。其中，28% 是计划内出版物，22% 是计划间出版物。